Drug profile · INN
riluzole
PHARMACOR RILUZOLE
riluzole (PHARMACOR RILUZOLE) is a sodium channel alpha subunit blocker. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — riluzole
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 10
- Programs
- 7
- Data quality
- 0.89
Quick answer
riluzole (PHARMACOR RILUZOLE) is a sodium channel alpha subunit blocker. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025027051
INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
granted -
WO 2024175803
COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES
granted -
WO 2024146923
INHIBITEURS DE POLYMÉRISATION DE TUBULINE
granted -
WO 2022234069
NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
granted -
EP 3144307
NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER
granted -
WO 2016085391
DÉRIVÉS DE BIS (SULFONAMIDE) ETLEUR UTILISATION COMME INHIBITEURS DE MPGES
granted -
WO 2016085392
DÉRIVÉS DE BIS (SULFONAMIDE) ET LEUR UTILISATION COMME INHIBITEURS DE MPGES
granted -
WO 2016071511
TRAITEMENT DU SYNDROME D'ACTIVATION MASTOCYTAIRE (SAMA) AVEC LE MASINITIB
granted -
US 7396860
Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
granted -
EP 1477166
Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
expired
Frequently asked questions
What is riluzole?
riluzole (PHARMACOR RILUZOLE) is a sodium channel alpha subunit blocker. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for riluzole?
PHARMACOR RILUZOLE is a marketed brand name for riluzole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of riluzole?
riluzole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.